FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260769311> ?p ?o ?g. }

• W2260769311 endingPage "32773" @default.
• W2260769311 startingPage "32761" @default.
• W2260769311 abstract "// Mingsong Wu 1, * , Shuhui Si 2, * , Yan Li 3 , Susan Schoen 2 , Guang-Qian Xiao 4 , Xueying Li 1 , Bin Tean Teh 5 , Guan Wu 1, 4 , Jindong Chen 1, 2 1 Department of Cell Biology and Genetics, Zunyi Medical University, Zunyi 563099, China 2 Kidney Cancer Research Laboratory, Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA 3 State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China 4 Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA 5 NCCS-VARI Translational Cancer Research Laboratory, National Cancer Centre, 169610, Singapore * These authors have contributed equally to this work Correspondence to: Jindong Chen, e-mail: Jindong_chen@URMC.rochester.edu Guan Wu, e-mail: guan_wu@URMC.rochester.edu Keywords: BHD, RCC, kidney cancer, mTOR, sirolimus Received: July 17, 2015      Accepted: September 09, 2015      Published: September 21, 2015 ABSTRACT Deficiency of tumor suppressor FLCN leads to the activation of the mTOR signaling pathway in human BHD-associated renal cell carcinomas (RCC). We have previously developed a renal distal tubule-collecting duct-Henle's loop-specific Flcn knockout (KO) mouse model ( Flcn flox/flox / Ksp-Cre ). This mouse model can only survive for three weeks after birth due to the development of polycystic kidney and uremia. Whether these cystic solid hyperplasia changes seen in those KO mice are tumorigenic or malignant is unknown. In this study, we demonstrated that genetic disruption of Flcn in mouse kidney distal tubule cells could lead to tumorigenic transformation of these cells to develop allograft tumors with an aggressive histologic phenotype. Consistent with previous reports, we showed that the mTOR pathway plays an important role in the growth of these Flcn-deficient allograft and human UOK 257-1 xenograft tumors. We further demonstrated that the mTOR inhibitor, sirolimus, suppresses the tumor's growth, suggesting that mTOR inhibitors might be effective in control of FLCN-deficient RCC, especially in BHD renal tumorigenesis." @default.
• W2260769311 created "2016-06-24" @default.
• W2260769311 creator A5010420032 @default.
• W2260769311 creator A5016306772 @default.
• W2260769311 creator A5034912978 @default.
• W2260769311 creator A5046624620 @default.
• W2260769311 creator A5059260725 @default.
• W2260769311 creator A5076351536 @default.
• W2260769311 creator A5078094295 @default.
• W2260769311 creator A5085969724 @default.
• W2260769311 creator A5088888341 @default.
• W2260769311 date "2015-09-21" @default.
• W2260769311 modified "2023-10-18" @default.
• W2260769311 title "Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression" @default.
• W2260769311 cites W1505250968 @default.
• W2260769311 cites W1565869947 @default.
• W2260769311 cites W1966064388 @default.
• W2260769311 cites W1969157667 @default.
• W2260769311 cites W1980402007 @default.
• W2260769311 cites W1981403280 @default.
• W2260769311 cites W1983810780 @default.
• W2260769311 cites W1984621921 @default.
• W2260769311 cites W1985370440 @default.
• W2260769311 cites W1996657997 @default.
• W2260769311 cites W1997836389 @default.
• W2260769311 cites W2003237662 @default.
• W2260769311 cites W2004027150 @default.
• W2260769311 cites W2008825756 @default.
• W2260769311 cites W2024578614 @default.
• W2260769311 cites W2026351725 @default.
• W2260769311 cites W2032848771 @default.
• W2260769311 cites W2036707213 @default.
• W2260769311 cites W2038637606 @default.
• W2260769311 cites W2043812467 @default.
• W2260769311 cites W2050650475 @default.
• W2260769311 cites W2056712195 @default.
• W2260769311 cites W2058562532 @default.
• W2260769311 cites W2068555261 @default.
• W2260769311 cites W2074392215 @default.
• W2260769311 cites W2076568661 @default.
• W2260769311 cites W2082245140 @default.
• W2260769311 cites W2087783778 @default.
• W2260769311 cites W2092050617 @default.
• W2260769311 cites W2093607033 @default.
• W2260769311 cites W2096426595 @default.
• W2260769311 cites W2101053994 @default.
• W2260769311 cites W2110394707 @default.
• W2260769311 cites W2112666000 @default.
• W2260769311 cites W2118309199 @default.
• W2260769311 cites W2119888873 @default.
• W2260769311 cites W2122974646 @default.
• W2260769311 cites W2128635723 @default.
• W2260769311 cites W2132463881 @default.
• W2260769311 cites W2141249786 @default.
• W2260769311 cites W2148455178 @default.
• W2260769311 cites W2149828323 @default.
• W2260769311 cites W2151237573 @default.
• W2260769311 cites W2153867442 @default.
• W2260769311 cites W2170486847 @default.
• W2260769311 cites W2171550928 @default.
• W2260769311 cites W2400559550 @default.
• W2260769311 cites W2431311088 @default.
• W2260769311 doi "https://doi.org/10.18632/oncotarget.5018" @default.
• W2260769311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741728" @default.
• W2260769311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26418749" @default.
• W2260769311 hasPublicationYear "2015" @default.
• W2260769311 type Work @default.
• W2260769311 sameAs 2260769311 @default.
• W2260769311 citedByCount "11" @default.
• W2260769311 countsByYear W22607693112016 @default.
• W2260769311 countsByYear W22607693112017 @default.
• W2260769311 countsByYear W22607693112018 @default.
• W2260769311 countsByYear W22607693112019 @default.
• W2260769311 countsByYear W22607693112020 @default.
• W2260769311 countsByYear W22607693112021 @default.
• W2260769311 crossrefType "journal-article" @default.
• W2260769311 hasAuthorship W2260769311A5010420032 @default.
• W2260769311 hasAuthorship W2260769311A5016306772 @default.
• W2260769311 hasAuthorship W2260769311A5034912978 @default.
• W2260769311 hasAuthorship W2260769311A5046624620 @default.
• W2260769311 hasAuthorship W2260769311A5059260725 @default.
• W2260769311 hasAuthorship W2260769311A5076351536 @default.
• W2260769311 hasAuthorship W2260769311A5078094295 @default.
• W2260769311 hasAuthorship W2260769311A5085969724 @default.
• W2260769311 hasAuthorship W2260769311A5088888341 @default.
• W2260769311 hasBestOaLocation W22607693111 @default.
• W2260769311 hasConcept C104317684 @default.
• W2260769311 hasConcept C126322002 @default.
• W2260769311 hasConcept C502942594 @default.
• W2260769311 hasConcept C54355233 @default.
• W2260769311 hasConcept C62478195 @default.
• W2260769311 hasConcept C71924100 @default.
• W2260769311 hasConcept C86554907 @default.
• W2260769311 hasConcept C86803240 @default.
• W2260769311 hasConcept C97329493 @default.
• W2260769311 hasConceptScore W2260769311C104317684 @default.
• W2260769311 hasConceptScore W2260769311C126322002 @default.
• W2260769311 hasConceptScore W2260769311C502942594 @default.

• next